¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"Cell, plasma"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • basosquamous cell carcinoma
    ¹Ù´ÚÆíÆò¼¼Æ÷¾ÏÁ¾, ±âÀúÆíÆò¼¼Æ÷¾ÏÁ¾
  • beta cell
    º£Å¸¼¼Æ÷
  • bipolar cell
    µÎ±Ø¼¼Æ÷
  • blast cell
    ¸ð¼¼Æ÷
  • blood cell
    Ç÷¾×¼¼Æ÷, Ç÷±¸
  • blood cell separator
    Ç÷±¸ºÐ¸®±â
  • bone marrow-derived cell
    °ñ¼öÀ¯·¡¼¼Æ÷
  • border cell
    °æ°è¼¼Æ÷, ¼Ó°æ°è¼¼Æ÷
  • balloon cell
    dz¼±¼¼Æ÷
  • balloon cell nevus
    dz¼±¼¼Æ÷¸ð¹Ý
  • bristle cell
    ¾ï¼¾Åм¼Æ÷, °­¸ð¼¼Æ÷
  • burr cell
    ¹«µòÅ鳯ÀûÇ÷±¸
  • ciliated cell
    ¼¶¸ð¼¼Æ÷
  • clear cell
    Åõ¸í¼¼Æ÷
  • clear cell acanthoma
    Åõ¸í¼¼Æ÷°¡½Ã¼¼Æ÷Á¾, Åõ¸í¼¼Æ÷±Ø¼¼Æ÷Á¾
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 10 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • transitional cell
    ÀÌÇ༼Æ÷
  • transitional cell carcinoma
    ÀÌÇ༼Æ÷¾ÏÁ¾
  • cell line
    ¼¼Æ÷ÁÖ
  • giant cell pneumonia
    °Å´ë¼¼Æ÷Æó·Å
  • giant cell tumor
    °Å´ë¼¼Æ÷Á¾
  • granular cell tumor
    °ú¸³¼¼Æ÷Á¾¾ç
  • granulosa cell tumor
    °ú¸³Ãþ¼¼Æ÷Á¾¾ç
  • sickle cell trait
    ³´¼¼Æ÷¼ÒÁú, ³´ÀûÇ÷±¸Çü¼º¼ÒÁú
  • packed cell volume
    ÃæÀü¼¼Æ÷¿ëÀû, ³óÃ༼Æ÷¿ëÀû
  • red cell distribution width
    ÀûÇ÷±¸ºÐÆ÷Æø
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • target cell anemia
    Ç¥ÀûÀûÇ÷±¸ºóÇ÷
  • balloon cell
    dz¼±¼¼Æ÷
  • balloon cell melanoma
    dz¼±¼¼Æ÷Èæ»öÁ¾
  • balloon cell nevus
    dz¼±¼¼Æ÷¸ð¹Ý
  • basal cell
    ¹Ù´Ú¼¼Æ÷, ±âÀú¼¼Æ÷
  • basal cell carcinoma
    ¹Ù´Ú¼¼Æ÷¾ÏÁ¾, ±âÀú¼¼Æ÷¾ÏÁ¾
  • basal cell epithelioma
    ¹Ù´Ú¼¼Æ÷»óÇÇÁ¾, ±âÀú¼¼Æ÷»óÇÇÁ¾
  • basal cell nevus
    ¹Ù´Ú¼¼Æ÷¸ð¹Ý, ±âÀú¼¼Æ÷¸ð¹Ý
  • basal cell nevus syndrome
    ¹Ù´Ú¼¼Æ÷¸ð¹ÝÁõÈıº, ±âÀú¼¼Æ÷¸ð¹ÝÁõÈıº
  • basket cell
    ¹Ù±¸´Ï¼¼Æ÷
  • basophilic cell
    È£¿°±â¼¼Æ÷
  • basosquamous cell carcinoma
    ¹Ù´ÚÆíÆò¼¼Æ÷¾ÏÁ¾, ±âÀúÆíÆò¼¼Æ÷¾ÏÁ¾
  • beta cell
    º£Å¸¼¼Æ÷
  • bipolar cell
    µÎ±Ø¼¼Æ÷
  • blood cell
    Ç÷¾×¼¼Æ÷, Ç÷±¸
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • plasma pepsinogen
    Ç÷ÀåÆé½Ã³ë°Õ
  • plasma protein
    Ç÷Àå´Ü¹éÁú(úìíìÓ±ÛÜòõ).
  • plasma protein
    Ç÷Àå´Ü¹é(Áú)
  • plasma protein binding
    Ç÷Àå´Ü¹é°áÇÕ.
  • plasma protein fraction =PCC
    Ç÷Àå´Ü¹éºÐȹ
  • plasma prothrombin time
    Ç÷ÀåÇÁ·ÎÆ®·Òºó ½Ã°£.
  • plasma renin activity
    Ç÷Àå·¹´ÑȰ¼ºµµ<--Ȱµ¿µµ>
  • plasma substitute
    Ç÷Àå´ë¿ëÁ¦.
  • plasma thrombokinin
    Ç÷À寮·Òº¸Å°´Ñ.
  • plasma thromboplastic factor
    Ç÷À寮·Òº¸ÇÃ¶ó½ºÆ¾ÀÎÀÚ.
  • plasma thromboplastin
    Ç÷À寮·Òº¸ÇÃ¶ó ½ºÆ¾.
  • plasma thromboplastin antecedent
    Ç÷À寮·Òº¸ÇÃ¶ó½ºÆ¾Àü±¸(îñÏÌ)¹°Áú
  • plasma thromboplastin antecedent =PTA
    ÇöóÁ<Ç÷Àå>Æ®·Òº¸ÇÃ¶ó½ºÆ¾Àü±¸¹°Áú (
  • plasma thromboplastin component =PTC
    ÇöóÁ<Ç÷Àå>Æ®·Òº¸ÇÃ¶ó½ºÆ¾¼ººÐ(¡­à÷ÝÂ
  • plasma thromboplastin component defic
    ÇöóÁ<Ç÷Àå>Æ®·Òº¸ÇÃ¶ó½ºÆ¾¼ººÐ°áÇÌ(Áõ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • plasma iron turnover rate
    Ç÷Àåö±³Ã¼À².
  • plasma lipoprotein abnormalities
    Ç÷ÀåÁöÁú´Ü¹éÁúÀÌ»óÁõ.
  • plasma membrane
    ¿øÇüÁú¸·(ê«û¡òõد), ¼¼Æ÷ÇüÁú¸·(á¬øàû¡òõد).
  • plasma membrane
    ¿øÇüÁú¸·
  • plasma membrane
    ÇüÁú¸·
  • plasma membrane
    ¿øÇüÁú¸·(ê«û¡òõد), ¼¼Æ÷ÇüÁú¸·(á¬øàû¡òõد).
  • plasma membrane
    ÇüÁú¸·
  • plasma membrane carnitine transport defect
  • plasma membrane of erythrocyte
    ÀûÇ÷±¸ÇüÁú¸·
  • plasma pepsinogen
    Ç÷ÀåÆé½Ã³ë°Õ
  • plasma protein
    Ç÷Àå´Ü¹é(Áú)
  • plasma protein
    Ç÷Àå´Ü¹éÁú(úìíìÓ±ÛÜòõ).
  • plasma protein binding
    Ç÷Àå´Ü¹é°áÇÕ.
  • plasma protein fraction =PCC
    Ç÷Àå´Ü¹éºÐȹ
  • plasma prothrombin time
    Ç÷ÀåÇÁ·ÎÆ®·Òºó ½Ã°£.
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • Outer phalangeal cell of Deiters
    ¹Ù±ù¼Õ°¡¶ô¼¼Æ÷
    [¿¾ ¿ë¾î] ¿ÜÁö»ó¼¼Æ÷
  • Outer hair cell
    ¹Ù±ùÅм¼Æ÷
    [¿¾ ¿ë¾î] ¿ÜÀ¯¸ð¼¼Æ÷
  • Basal epithelial cell
    ¹Ù´Ú»óÇǼ¼Æ÷
    [¿¾ ¿ë¾î] ±âÀúÃþ»óÇǼ¼Æ÷
  • Basal cell
    ¹Ù´Ú¼¼Æ÷
    [¿¾ ¿ë¾î] ±âÀú¼¼Æ÷
  • Fusiform myoepithelial cell
    ¹æÃß±ÙÀ°»óÇǼ¼Æ÷
    [¿¾ ¿ë¾î] ¹æÃß»ó±Ù»óÇǼ¼Æ÷
  • Fusiform endothelial cell
    ¹æÃß³»ÇǼ¼Æ÷
    [¿¾ ¿ë¾î] ¹æÃß»ó³»ÇǼ¼Æ÷
  • Sustentacular cell
    ¹öÆÀ¼¼Æ÷
    [¿¾ ¿ë¾î] ÁöÁÖ¼¼Æ÷
  • Parietal cell
    º®¼¼Æ÷
    [¿¾ ¿ë¾î] º®¼¼Æ÷
  • Stellate myoepithelial cell
    º°±ÙÀ°»óÇǼ¼Æ÷
    [¿¾ ¿ë¾î] ¼º»ó±Ù»óÇǼ¼Æ÷
  • Stellate cell
    º°¼¼Æ÷
    [¿¾ ¿ë¾î] ¼º»ó¼¼Æ÷
  • Cell of parathyroid gland
    ºÎ°©»ó»ù¼¼Æ÷
    [¿¾ ¿ë¾î] ºÎ°©»ó¼±¼¼Æ÷
  • Secretory synovial cell
    ºÐºñÀ±È°¼¼Æ÷
    [¿¾ ¿ë¾î] Ȱ¸·ºÐºñ¼¼Æ÷
  • Mast cell
    ºñ¸¸¼¼Æ÷
    [¿¾ ¿ë¾î] ºñ¸¸¼¼Æ÷
  • Intercalated epithelial cell
    »çÀÌ»óÇǼ¼Æ÷
    [¿¾ ¿ë¾î] Áß°£Ãþ»óÇǼ¼Æ÷
  • Interstitial cell
    »çÀÌÁú¼¼Æ÷
    [¿¾ ¿ë¾î] °£Áú¼¼Æ÷
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • enucleated cell
    Á¦ÇÙ ¼¼Æ÷ (ð¶ú·á¬øà)
  • established cell line
    ¼ö¸³ ¼¼Æ÷ÁÖ (â§Ø¡á¬øàñ»)
  • feeder cell
    °ø±ÞÀÚ¼¼Æ÷ (ÍêÐåíºá¬øà)
  • flow cell
    È帧 ½Ç(ãø)
  • founder cell
    ½ÃÁ¶ ¼¼Æ÷(ã·ðÓá¬øà)
  • germ cell
    ¹è¼¼Æ÷(ÛÏá¬øà)
  • germinal cell
    ¹è¾Æ¼¼Æ÷(ÛÏä´á¬øà)
  • glial cell
    ½Å°æ±³¼¼Æ÷(ãêÌèÎïá¬øà)
  • half-cell
    ¹Ý½Ç(Úâãø)
  • helper T cell
    µµ¿òÀÌ T ¼¼Æ÷(á¬øà)
  • host-cell reactivation
    ¼÷ÁÖ ¼¼Æ÷ ÀçȰ¼ºÈ­(âÖñ«á¬øàî¢üÀàõûù)
  • hybrid cell
    Æ¢±â¼¼Æ÷(á¬øà)
  • I-cell disease
    I-¼¼Æ÷ Áúȯ(á¬øàòðü´)
  • immune competent cell
    ¸é¿ª Àû°Ý ¼¼Æ÷(Øóæ¹îêÌ«á¬øà)
  • immunocompetent cell
    ¸é¿ªÀû°Ý¼¼Æ÷(Øóæ¹îêÌ«á¬øà)
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 2 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • tumor cell
    Á¾¾ç¼¼Æ÷
  • white blood cell
    ¹éÇ÷±¸
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 5
GCT general care and treatment; germ-cell tumor; giant cell thyroiditis; giant cell tumor
RCC radiological control center; rape crisis center; ratio of cost to charges; receptor-chemoeffector co...
SC conditioned stimulus; sacrococcygeal; Sanitary Corps; scalenus [muscle]; scapula; Schwann cell; scia...
SCA self-care agency; severe congenital anomaly; sickle-cell anemia; single-camera autostereoscopic [ima...
SCC self-care center; sequential combination chemotherapy; services for crippled children; short-course ...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 5
ICP-AES Inductively Coupled Plasma-Atomic Emission Spectroscopy
ICP Inductively coupled plasma emission spectrometry
LPDP Lipoprotein-deficient plasma
LPM Liver plasma membranes
L/P Lymph/plasma
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • basal cell hyperplasia
    ±âÀú ¼¼Æ÷ °úÇü¼º
  • basal cell nevus
    ±âÀú ¼¼Æ÷ ¸ð¹Ý
  • basal cell papilloma
    ±âÀú ¼¼Æ÷ À¯µÎÁ¾
  • basal-cell layer
    ±âÀú ¼¼Æ÷Ãþ
  • basophilic cell
    È£¿°±â¼º ¼¼Æ÷
  • basosqumaous cell acanthoma
    ±âÀú ÆíÆò ¼¼Æ÷ ±Ø¼¼Æ÷Á¾
  • benign giant cell tumor
    ¾ç¼º °Å´ë¼¼Æ÷ Á¾¾ç
    1. °ñÀÇ ¾ç¼º °Å´ë¼¼Æ÷Á¾. °ñÀÇ ¾ç¼º Á¾¾çÀÇ Çϳª·Î ³ë¾àÀÚ¿¡°Ô ¸¹À¸¸ç ¹ß»ý ºÎÀ§´Â Àå°ü°ñÀÇ °ñ´Ü¿¡ ¸¹ÀÌ ³ªÅ¸³­´Ù. Á¶Á÷ÇÐÀûÀ¸·Î ¿øÇü, ¹æÃßÇüÀÌ ÀÖ´Ù. ¼¼Æ÷ »çÀÌ¿¡ ÆÄ°ñ¼¼Æ÷¿Í À¯»çÇÑ °Å´ë¼¼Æ÷°¡ È¥ÀçÇÑ´Ù. 2. °ÇÃÊÀÇ ¾ç¼º °Å´ë¼¼Æ÷Á¾. º»·¡ Á¾¾çÀÌ ¾Æ´Ï¸ç, °áÁ¤¼º °ÇÃÊ¿°À» °¡¸®Å°¸ç °ÇÃÊÀÇ ¼¶À¯¼º Á¶Á÷±¸Á¾¿¡ Æ÷ÇԵȴÙ.
  • beta cell tumor
    º£Å¸ ¼¼Æ÷Á¾
  • beta-cell tumor
    º£Å¸ ¼¼Æ÷ Á¾¾ç
    µµ¼¼Æ÷ Á¾¾ç Áß °¡Àå ÈçÇÑ Áúº´À¸·Î Àν¶¸° °ú´Ù ºÐºñ°¡ ÀϾ´Ù.
  • bipolar cell
    µÎ ±Ù ½Å°æ¼¼Æ÷, ½Ö±Ø ¼¼Æ÷
    µÎ °³ÀÇ µ¹±â¸¦ °¡Áø ½Å°æ¼¼Æ÷.
  • blood cell counter
    Ç÷±¸ °è¼ö±â
  • bone cell
    °ñ ¼¼Æ÷
    °ñÁ¶Á÷ÀÇ ±âº» ¼¼Æ÷. °ñ Á¶Á÷¿¡´Â µüµüÇÑ °ñ ±âÁú¾È¿¡ °ñ¼Ò°­À̶ó°í ÇÏ´Â Æ´ÀÌ ±ºµ¥±ºµ¥ ÀÖ°í, ±× ¼Ó¿¡ 1°³¾¿ÀÇ °ñ ¼¼Æ÷°¡ µé¾î ÀÖ´Ù. °ñ ¼¼Æ÷ÀÇ ÇüÅ´ °ñ¼Ò°­°ú ÀÏÄ¡ÇÏ¿© ÆíÆòÇÑ Å¸¿øÇüÀ¸·Î, ±æÀÌ´Â 15¡­27 ¥ìmÀÌ´Ù. °ñ ¼¼Æ÷´Â ´Ù¼öÀÇ °¡´Â ¿øÇüÁú µ¹±â°¡ À־, À̰ÍÀÌ ±âÁú ³»ÀÇ °ñ ¼¼°üÀ» ÅëÇÏ¿© °¡±îÀÌ ÀÖ´Â °ñ ¼¼Æ÷ÀÇ µ¹±â¿Í ÇÕÄ£´Ù. °ñ ¼¼Æ÷´Â º»·¡ °áÇÕÁ¶Á÷ÀÇ ¼¶À¯¾Æ¼¼Æ÷¿¡¼­ Çü¼ºµÇ´Â °ÍÀ¸·Î, ¸ÕÀú °ñ¾Æ¼¼Æ÷°¡ µÇ¾î, À̰ÍÀÌ ±âÁúÀ» ¸¸µé°í ÀÚ½ÅÀº ±× ±âÁú ¼Ó¿¡ µé¾î°¡ °ñ¼¼Æ÷·Î µÈ´Ù. À̰ÍÀº °ñ Á¶Á÷ÀÇ Á¦Á¶ÀÚÀ̸ç, ¼¼Æ÷ÁúÀº ¹Ì·®ÀÇ ¹ÌÅäÄܵ帮¾Æ¸¦ Æ÷ÇÔÇϰí, È£¾à¿°±â¼ºÀ» ³ªÅ¸³½´Ù.
  • bone marrow cell
    °ñ¼ö ¼¼Æ÷
  • bristle cell
    °­¸ð ¼¼Æ÷, ¸ð¼¼Æ÷
  • calcigerous cell
    ¼®È¸È­ ¼¼Æ÷
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
salted plasma The fluid portion of blood drawn from the vessels, which is prevented from coagulating by being drawn into a solution of sodium or magnesium sulfate.
Synonym: salted serum.
(05 Mar 2000)
human plasma protein fraction A sterile solution of selected proteins derived from the blood plasma of adult human donors, containing 4.5 to 5.5 g of protein per 100 ml, of which 83 to 90% is albumin and the remainder is alpha-and beta-globulins; used as a blood volume supporter.
(05 Mar 2000)
standing plasma test If plasma is stored at 4°C upright in a test tube, chylomicrons will float to the top and form a creamy layer.
(05 Mar 2000)
normal human plasma Sterile plasma obtained by pooling approximately equal amounts of the liquid portion of citrated whole blood from eight or more adult humans who have been certified as free from any disease which is tranmissible by transfusion, and treating it with ultraviolet irradiation to destroy possible bacterial and viral contaminants.
(05 Mar 2000)
dried human plasma protein fraction Freeze-dried human plasma protein fraction.
(05 Mar 2000)
d-shaped plasma <radiobiology> A toroidal plasma whose cross-section (poloidal plane) is a D (instead of a circle). A D-shape has a higher beta limit than a circular shape.
(09 Oct 1997)
quasineutral plasma <physics> An ionised gas in which positive and negative charges are present in approximately equal numbers.
(09 Oct 1997)
target plasma <radiobiology> Plasma used to trap a neutral atom beam. A background plasma of sufficiently high density and temperature can ionize neutral atoms more effectively than the Lorentz process (where v cross B creates effective electric field).
(09 Oct 1997)
temperature, plasma <radiobiology> A measure of the random (thermal) kinetic energy of the ions or electrons in the plasma. The temperature of each component of a plasma depends on the mean kinetic energy of that component. An example of this is the fluorescent light bulb, which is an example of a weakly-ionised plasma where the electrons are at temperatures of tens of thousands of degrees, whereas the ions and neutrals are much cooler (so that you can touch the bulb without being burned).
See: atomic temperature, electron temperature, ion temperature.
(09 Oct 1997)
edge plasma <radiobiology> Cooler, less dense plasma away from the centre of a reactor, affected by limiter or divertor, includes scrape-off layer. Distinguished from core plasma.
(09 Oct 1997)
effective renal plasma flow <physiology> The amount of plasma flowing to the parts of the kidney that have a function in the production of constituents of urine; the clearance of substances such as iodopyracet and p-aminohippuric acid, assuming that the extraction ratio in the peritubular capillaries is 100%.
It is the amount of plasma perfusing the kidney tubules per unit time, generally measured by p-aminohippurate clearance. It should be differentiated from renal plasma flow which is approximately 10% greater than the effective renal plasma flow.
(07 Mar 2000)
two-component plasma <radiobiology> Refers to a plasma containing a cool thermal component and a population of high energy particles (such as from neutral beam injection) which are in the process of thermalising (slowing down).
(09 Oct 1997)
kern-plasma relation theory A theory enunciated by Hertwig (1903) that a definite relation as to size normally exists in every cell between the mass of nuclear material and that of the protoplasm.
Origin: Ger. Kern, kernel, nucleus
(05 Mar 2000)
fresh frozen plasma The fluid component of blood lacking the cells but containing all the necessary plasma proteins, used to restore the protein clotting factors in some individuals with clotting factor deficiencies.
(27 Sep 1997)
T-cell-rich, B-cell lymphoma <tumour> A B-cell lymphoma in which more than 90% of the cells are of T-cell origin, masking the large cells that form the neoplastic B-cell component.
See: adult T-cell lymphoma.
(05 Mar 2000)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 5
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 5
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 5
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 5
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 5
ÅëÇÕ°Ë»ö ¿Ï·á